VIDEO From Medialink: FDA Approves First Drug to Help Patients With Parkinson's Disease Dementia
Posted on: Thursday, 10 August 2006, 21:00 CDT
According to the National Parkinson Foundation (NPF), dementia is one of the complications most feared by Parkinson's disease patients and caregivers. Of the 1.5 million Americans living with the disease, an estimated 40% develop dementia.
(See video at: http://media.medialink.com/WebNR.aspx?story=32280 )
The U.S. Food and Drug Administration (FDA) has approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate Parkinson's disease dementia, making it the first approved medication available for the treatment of this condition.
The risk of developing dementia is approximately four to six times higher among Parkinson's patients than among elderly people without the disease. The primary symptoms of Parkinson's disease dementia include cognitive impairment and neuro-psychiatric symptoms (e.g., depression, hallucinations, anxiety and apathy). These symptoms impact the patient's quality of life, course of the disease and caregiver distress.
While this drug is now being used to treat Parkinson's patients with dementia, for years it has been used in the treatment of Alzheimer's disease.
Registered journalists can access video, audio, text, graphics and photos for free, with unrestricted use at http://media.medialink.com.
Source: Business Wire
Related Articles
- OR-Live.Com Presents: Early Intervention in the Treatment of Mitral Valve Disease: Clinical Guidelines, Treatment Options &Amp; Patient Benefits
- Highly Promising Dutch Research Into Alzheimer's Disease and Parkinson's Disease
- Parkinson's Disease Dementia is Studied
- PatientsLikeMe Unleashes Real-World Treatment and Symptom Information to the Public for ALS and Multiple Sclerosis
- Medialink Features: First and Only Treatment Now Available for Mild-to-Moderate Parkinson's Disease Dementia
- Parkinson's Treatment Reduces Symptoms
- Valeant Launches New Parkinson's Treatment in US
- The U.S. Food and Drug Administration Approves Exelon(R) (Rivastigmine Tartrate) As the First Medication Indicated to Treat Parkinson's Disease Dementia
- Multimedia News Release - Concern, Confusion Over Treatment of Symptoms of Menopause
User Comments (0)

RSS Feeds